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Summary
Two pediatric patients with different causes of hyperparathyroidism are reported. First patient is a 13-year-old male with 
severe hypercalcemia due to left upper parathyroid gland adenoma. After successful surgery, calcium and phosphate 
levels normalized, but parathormone levels remained elevated. Further studies revealed a second adenoma in the right 
gland. The second patient is a 13-year-old female with uncommon hypercalcemia symptoms. Presence of pathogenic 
calcium-sensing receptor gene (CASR) mutation was found, resulting in diagnosis of symptomatic familial hypocalciuric 
hypercalcemia. Cinacalcet, a calcium-sensing agent that increases the sensitivity of the CASR, was used in both patients 
with successful results.
Background
Hypercalcemia is an uncommon clinical problem in 
pediatric patients. Etiologies vary with age at diagnosis, 
and include parathyroid adenoma or hyperplasia, 
mutations affecting calcium-sensing receptor (CaSR), 
hypervitaminosis D, inborn errors of metabolism or 
iatrogenic factors, among others. Hyperparathyroidism, 
which can be primary or secondary, is caused by an 
excessive production of parathyroid hormone by the 
parathyroid gland. Parathyroid adenoma is the most 
common cause of primary hyperparathyroidism (PHPT). 
In most cases, it is isolated and the recommended 
treatment is surgery.
On the other hand, familial hypocalciuric 
hypercalcemia (FHH) is generally considered a benign 
disease. It is caused by heterozygous mutation of the CASR 
gene and most patients are asymptomatic.
Cinacalcet has been successfully used in adults with 
PHPT. In pediatric patients, it is a drug generally used for 
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Learning points:
 • Hyperparathyroidism is a rare condition in pediatric patients. If not treated, it can cause serious morbidity.
 • Genetic tests searching for CASR or MEN1 gene mutations in pediatric patients with primary hyperparathyroidism 
should be performed.
 • Cinacalcet has been effective for treating different causes of hyperparathyroidism in our two pediatric patients.
 • Treatment has been well tolerated and no side effects have been detected.
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treatment of secondary hyperparathyroidism. However, 
its use in PHPT is exceptional.
Case 1 presentation
A 13-year-old male from Senegal underwent a medical 
examination at his arrival in Spain. There was no personal 
or familial history of pathology related to hypercalcemia. 
Physical examination showed weight at 26 kg (−2.7 
SDS), height at 130 cm (−4 SDS) (Table  1) with Tanner 
stage II, sable deformity in forearms and left genus valgus 
(Fig.  1). He did not display any clinical symptom. In 
whole-body skeletal survey, Looser–Milkman lines were 
observed in both tibias, as well as diffuse osteoporosis 
with bone reabsorption signs (Figs  2, 3, 4 and 5). A 
blood test showed hypercalcemia: 13.8 mg/dL (8.8–10.6), 
hypophosphatemia: 2.9 mg/dL (3–5), parathormone 
(PTH): 1250 pg/dL (14.5–87.1), alkaline phosphatase: 
1587 IU/L (50–162) and severe vitamin D deficiency: 
7.9 ng/mL (Table 2).
Case 1 investigation
The patient was referred to a tertiary pediatric hospital, 
where further studies were performed. Urine analysis 
reported elevated calciuria. Severe nephrocalcinosis was 
revealed in the abdominal ultrasound. Ultrasonography, 
cervical scan and sestamibi-Tc99m scintigraphy showed 
a left parathyroid adenoma of 12 × 10 × 45 mm. Genetic 
study of the CASR and MEN1 genes did not show any 
alteration.
Case 1 treatment
Prior to surgery, calcidiol was started. The procedure 
was undergone without incidences or complications. 
Pathological anatomy confirmed a 2.4 g weight adenoma 
without malignancy.
Immediate follow-up showed normal calcium, 
phosphate and vitamin D levels, but PTH values were 
persistently elevated (250 pg/dL). Four months after 
surgery, cervical MRI and scintigraphy were performed 
again and a 12 × 8 × 4.9 mm right parathyroid adenoma 
was found. Images performed at diagnosis of the first 
adenoma were revised. There was no evidence of previous 
misdiagnosis.
Given the complex surgical approach and the 
normality of calcium values, and after obtaining the 
informed consent and authorization of compassionate 
Table 1 Clinical presentation and diagnosis of the two patients.
Clinical presentation Patient 1 Patient 2
Symptoms None Dizziness, weakness and limiting fatigue
Physical examination Weight: −2.7 SDS, height: −4 SDS, sable deformity in 
forearms, left genus valgus. Osteoporosis with bone 
reabsorption signs
No alteration found
Final diagnosis Left: 12 × 10 × 45 mm parathyroid adenoma; right: 
12 × 8 × 4.9 mm parathyroid adenoma
Symptomatic familial hypocalciuric 
hypercalcemia; heterozygous CASR 
mutation
Time from diagnosis until 
cinacalcet
4 months after surgery of first adenoma 2 months 
Figure 1
Patient 1 at diagnosis. Important left genus valgus is observed.
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drug use, treatment with 30 mg/24 h cinacalcet was 
initiated. No acute hypocalcemia or other side effects 
were reported. Dosage was doubled after 6 months due to 
the rebound of calcium levels. The patient also underwent 
epiphysiodesis in left femur and tibia.
Case 1 outcome and follow-up
Currently, this patient receives 1000 IU/24 h vitamin D 
and 30 mg/12 h cinacalcet. After 18-month follow-up, 
patient remains without symptoms, has gained height 
(+1.3 SDS) (Fig. 5) and has normal values of calcium, PTH 
and calciuria (Table 2).
Case 2 presentation
A 13-year-old female presented with dizziness, muscular 
weakness and limiting fatigue. She had no significant 
previous personal or familial history of pathology. Height, 
weight and BMI were adequate for age with Tanner stage 
IV; hypercalcemia: 12.4 mg/dL, ionic calcium: 1.49 mmol/l 
(1.12-1.32) and hypophosphatemia: 2.8 mg/dL; no other 
abnormalities in hematology or biochemistry were found. 
She had no previous calcium determinations.
Case 2 investigation
Further studies showed PTH: 113 pg/mL, vitamin D: 32 ng/
mL and abnormally normal urinary calciuria (Table  2). 
Image studies of the parathyroid gland were normal. Bone 
densitometry showed 0.934 g/cm2 (−0.1 SDS).
Genetic study of the CASR showed a non-previously 
described pathogenic mutation of c. 2446A<G; P. 
lle816Val. The same mutation was found in the mother, 
who had no symptoms and serum calcium: 10.6 mg/dL, 
phosphate: 2.9 mg/dL, calcium/creatinine: 0.7 mg/mg, 
PTH 31 pg/mL and vitamin D: 26 ng/mL.
As FHH is usually asymptomatic, pulmonary CT, 
spirometry, allergy tests, electrocardiogram and cardiac 
stress test were also performed. No alterations were found.
Case 2 treatment
After obtaining the informed consent and authorization 
of compassionate drug use, cinacalcet 30 mg/24 h was 
initiated. She presented no acute hypocalcemia or other 
Figure 2
Patient 1 at diagnosis. Sable deformity, and diffuse osteoporosis with 
bone reabsorption signs is observed. D: right arm
Figure 3
Patient 1 at diagnosis. Diffuse osteoporosis with bone reabsorption signs 
is observed.
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side effects. Calcium, phosphate and PTH levels returned 
progressively to normal.
Case 2 outcome and follow-up
After 1  year of treatment, patient had serum calcium: 
10.3 mg/dL, phosphate: 3.8 mg/dL, PTH: 52 pg/mL 
and urinary calcium/creatinine: 0.22 mg/mg (0.2–0.4) 
(Table  2). She currently reports no dizziness, fatigue or 
other symptoms.
Discussion
Cinacalcet is a calcium-mimetic agent capable of 
increasing the sensitivity of the CASR to extracellular 
calcium, resulting in reduction of PTH secretion and 
therefore reducing serum calcium levels (1). Several 
studies have shown that it is effective for the treatment 
of secondary hyperparathyroidism (SHPT) and also PHPT 
in adults (2, 3).
In the pediatric population, cinacalcet has been 
proved useful in avoiding parathyroidectomy and 
reducing the need of bisphosphonates in severe neonatal 
Figure 4
Patient 1 at diagnosis. Diffuse osteoporosis with bone reabsorption signs 
is observed.
Figure 5
Patient 1 one year after surgery of the parathyroid adenoma, genus 
valgus and cinacalcet therapy.
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hyperparathyroidism, caused by homozygous mutations 
with loss-of-function of the CASR gene (4). Ongoing 
studies are to determine whether its effect also benefits 
children with SHPT (5, 6). However, no significant 
evidence has yet been published regarding the effects of 
cinacalcet in the pediatric population, either in PHPT or 
in cases of FHH.
Regarding the first patient, physical examination at 
diagnosis showed serious consequences of untreated PHPT. 
Although he reported no symptoms, bone alterations 
described were likely to already have caused multiple 
limitations to growth, development and morbidity.
The main aim of management in children with PHPT 
is to control hypercalcemia. Surgery is both safe and 
effective. It is considered the most appropriate treatment 
for symptomatic parathyroid adenoma (7, 8). The choice 
of operating technique, which includes bilateral neck 
exploration or minimally invasive parathyroidectomy, 
depends on the underlying etiology (2). Our patient 
underwent a minimally invasive procedure without 
complications.
Recurrent hyperparathyroidism after 
parathyroidectomy occurs in a low proportion of children 
and it is mostly associated with familial forms such as 
MEN syndromes or CASR mutations (9). It is well known 
that mutations of the suppressive tumor gene Menin are 
responsible for MEN 1, an autosomal dominant disease 
that causes predisposition to tumors of the parathyroid 
glands, anterior pituitary and pancreatic islet cells. Both 
genetic tests were negative in our first patient.
On the other hand, the CASR gene encodes the 
calcium-sensing receptor, a G-protein receptor highly 
expressed in the parathyroid and the kidney. More than 
200 different mutations have been described for the CASR 
(http://www.casrdb.mcgill.ca, searched August 2017). 
Most of them are inactivating and cause loss-of-function, 
causing a reduction in the sensitivity to extracellular 
calcium and consequently an increase in the parathyroid 
secretion of PTH and a decrease of the calcium renal 
excretion. This usually results in FHH. A non-previously 
described mutation of CASR gene c. 2446A<G; P. lle816Val 
was found in our second patient, which is described as 
pathogenic by prediction software (Polyphen-2, Mutation 
Taster).
There was no previous evidence of familial 
hyperparathyroidism in our patients. Calcium, phosphate 
and PTH levels were studied in the father of the first 
patient with normal results. Studying the mother was 
not an option because she lives abroad. Nevertheless, the 
mother of the second patient tested positive for the same Ta
b
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mutation. In these asymptomatic cases of FHH, treatment 
is not recommended.
However, the second patient had symptomatic 
hypercalcemia. Although she did not describe nausea, 
constipation or other digestive disturbances, uncommon 
symptoms such as muscular weakness, dizziness and 
fatigue were present.
Finally, cinacalcet therapy was considered in our 
patients for different reasons: In the first patient, due to 
the lack of symptoms, normal serum determinations of 
calcium and phosphate, negative molecular study, recent 
previous surgery and the anatomical location of the 
second adenoma. In the second patient, it was the fact 
that hypercalcemia could not be ruled out as the cause of 
symptoms presented.
Treatment was started in both patients at initial doses 
of 30 mg/24 h. They did not present acute hypocalcemia, 
digestive intolerance or any of the most common adverse 
effects described, such as nausea, headache, arthralgia or 
myalgia (10). Moreover, treatment has been well tolerated 
after more than 18 months of follow-up.
In conclusion, this report contributes to illustrate the 
important effects of PHPT and to expand the knowledge 
of cinacalcet therapy in the pediatric population. 
Cinacalcet was safe and well tolerated. Furthermore, 
it resulted effective in both patients. In the first one, 
it has avoided new surgery, and the second patient 
refers improvement of symptomatology. However, the 
future and long-term evolution of both cases remains 
uncertain.
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